Pulmonary Drug Delivery Systems Market size is valued at USD 52,670.16 million in 2021 and is expected to reach USD 78,156.36 million by 2028, at a CAGR of 5.8% during the forecast period 2022-2028. Pulmonary drug delivery systems helps to treat diseases such as asthma, cystic fibrosis. The pulmonary route is used in the treatment of various respiratory disorders. The pulmonary drug delivery is gaining popularity owing to its target specificity. The pulmonary drug delivery system delivers the medication thorough the respiratory tract. It is majorly used in the treatment of the conditions such as delivery of locally acting drugs directly to the sites of action. In December 2017, Sunovion receives the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Lonhala Magnair (glycopyrrolate) Inhalation Solution, also known as SUN-101/eFlow, for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Industry trends in the market are evolving, which will aid players in developing successful long-term strategies. Both established and emerging markets have implemented business growth techniques. COVID-19 is an unprecedented worldwide public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the projection period. Our continuous study is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included. The research examines COVID-19 in light of changes in consumer behaviour and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. Pulmonary Drug Delivery Systems Market research report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.